PTC reports preliminary data from Phase II of RG7916 for SMA type 1

PTC Therapeutics Inc. (NASDAQ:PTCT) and partner Roche (SIX:ROG; OTCQX:RHHBY) reported preliminary data from the pivotal Phase II FIREFISH trial of RG7916 (RO7034067) to treat infants with spinal muscular atrophy (SMA) type 1. In 13 evaluable patients who received once-daily oral RG7916 in the trial’s dose-finding first part,

Read the full 471 word article

User Sign In